Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Piper Sandler has maintained its Overweight rating on Kymera Therapeutics (NASDAQ:KYMR) and increased its price target from $39.00 to $56.00. Kymera's shares are slightly down by 0.07% at $43.41. The new price target suggests a potential 29.0% increase. Kymera is a biotech company focused on targeted protein degradation to treat diseases with its Pegasus platform.
February 27, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains Overweight rating on Kymera Therapeutics, raising price target to $56, indicating a potential 29% upside from the current price.
The upgrade in price target by Piper Sandler reflects a strong vote of confidence in Kymera Therapeutics' technology and market potential. Given the firm's influence, this could lead to increased investor interest and potentially drive the stock price up in the short term. The slight current dip in share price might offer a buying opportunity before the anticipated rise towards the new target.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100